(A-C) Effect of hrOSM on proliferation and migration of HSC/MFs cells. Proliferation assay (A) Boyden's chamber assay (B) and wound healing assay (C) were performed on HSC/MFs exposed to PDGF-BB 10 ng/mL, used as positive control, or to hsOSM 10 ng/mL. Data in bar graphs represent mean SEM (n = 3, in triplicate). *p < 0.05, **p < 0.01 versus control value. , and then exposed to OSM 10 ng/mL for 1 h (A). Boyden's chamber assay (A) and wound healing assay (B) were performed on HSC/MFs cells treated with hrOSM 10 ng/mL or ,where indicated, pre-treated for 1 h with apocynin, the pharmacological inhibitor of the NADPH oxidase (APO 250 µ M), or with the JAK2 inhibitor (AG490 100 µ M) and then exposed to OSM 10 ng/mL. *p < 0.05, versus control value, #p < 0.01 versus OSM value. . Western blotting analysis of VEGF protein levels in HSC/MFs treated with hrOSM 10 ng/mL from 16 to 48 h (C). Equal loading was confirmed by reprobing the same membrane with -action. Wound healing assay (D) in HSC/MFs untreated or exposed to medium (OSMm) obtained from HSC/MFs treated with OSM for 48 h or, where indicated, pre-treated with the neutralizing antibody for VEGFR2 or with the pharmacological inhibitro of VEGFR2, SU1498 and then exposed to OSMm. *p < 0.05, versus control value, #p < 0.05; versus OSMm value.
